Multimodal neuroimaging and neurocognitive assessment in adolescents with and without sickle cell disease

D David Wilson (Biologics Discovery, Teva Pharmaceutical Industries Ltd.) S Simon Chung (Department of Biostatistics, University of Arkansas for Medical Sciences) B Bianca Mahomes (3Arkansas Children's Research Institute, Little Rock, United States) T Trenesha Hill (4University of Arkansas for Medical Sciences, Pediatrics, Little Rock, United States) S Shelley Crary (1Arkansas Children's Hospital/ University of Arkansas for Medical Sciences, Little Rock, United States) S Suzanne Saccente (1University of Arkansas for Medical Sciences, Pediatric Hematology/Oncology, Little Rock, United States) M Medhavi Honhar (1University of Arkansas for Medical Sciences, Pediatric Hematology/Oncology, Little Rock, United States) R Raghu Ramakrishnaiah (2Arkansas Children's Hospital, Little Rock, United States) T Timothy Koscik (Arkansas Children’s Research Institute) E Ellen Van Der Plas (1University of Arkansas for Medical Sciences, Pediatric Hematology/Oncology, Little Rock, United States)

Abstract

Abstract Objective Neurocognitive complications in pediatric sickle cell disease (SCD)—even without overt stroke—are increasingly recognized, yet adolescents remain underrepresented in research. Adolescence is a critical window for brain maturation, particularly in regions supporting executive function, which are metabolically demanding and vulnerable to oxygen and nutrient deficits. This ongoing study aimed to characterize neurodevelopmental alterations in adolescents with SCD using comprehensive neurocognitive testing and multimodal MRI. Methods African American adolescents aged 12–17 years with severe SCD (HbSS or HbS/β⁰-thalassemia) and controls were enrolled. Stroke history was an exclusion criterion. Participants underwent a single visit including computerized neurocognitive assessment (NIH Toolbox), multimodal 3T MRI, and blood sampling. MRI protocols assessed cerebral perfusion (arterial spin labeling), brain structure (T1/T2-weighted imaging), metabolite levels (magnetic resonance spectroscopy), and white matter integrity (diffusion tensor imaging). Multivariable linear models included group and age as predictors. Results Sixteen participants (10 with SCD, 6 controls; mean age = 15.3 years; 53% female) were included. Adolescents with SCD showed significantly poorer executive function than controls (mean score: 89 vs. 109; p = 0.006). Cerebral perfusion was elevated in patients across all regions (p < 0.05). Significant group differences were observed in metabolite levels, including glutathione (difference (95% CI) = 0.07 [0.03, 0.11], p = 0.002), N-acetylaspartate (0.26 [0.04, 0.48], p = 0.025), and glycerophosphocholine (0.05 [0.01, 0.09], p = 0.015). Poorer executive function was associated with increased perfusion in the cerebrum (β = –1.60 [-2.61, -0.59], p = 0.005), cerebellum (β = -1.67 [-2.62, -0.73], p = 0.002), hippocampus (β = -0.93 [-1.75, -0.11], p = 0.029), and amygdala (β = -1.08 [-2.06, -0.10], p = 0.034). Reduced volumes of the hippocampus (β = -74.34 [-148.52, -0.17], p = 0.050), caudate (β = -68.12 [-131.54, -4.70], p = 0.037), and putamen (β = -105.99 [-193.15, -18.84], p = 0.021) were also significantly associated with executive dysfunction. Conclusion This study demonstrates that adolescents with SCD, even without stroke, show measurable disruptions in executive function that are potentially linked to altered perfusion, metabolite imbalance, and structural brain differences. These findings underscore the utility of multimodal neuroimaging in uncovering hidden neurodevelopmental vulnerabilities and support the need for targeted interventions during adolescence.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 2968-2968
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (10)

D

David Wilson

Biologics Discovery, Teva Pharmaceutical Industries Ltd.

S

Simon Chung

Department of Biostatistics, University of Arkansas for Medical Sciences

B

Bianca Mahomes

3Arkansas Children's Research Institute, Little Rock, United States

T

Trenesha Hill

4University of Arkansas for Medical Sciences, Pediatrics, Little Rock, United States

S

Shelley Crary

1Arkansas Children's Hospital/ University of Arkansas for Medical Sciences, Little Rock, United States

S

Suzanne Saccente

1University of Arkansas for Medical Sciences, Pediatric Hematology/Oncology, Little Rock, United States

M

Medhavi Honhar

1University of Arkansas for Medical Sciences, Pediatric Hematology/Oncology, Little Rock, United States

R

Raghu Ramakrishnaiah

2Arkansas Children's Hospital, Little Rock, United States

T

Timothy Koscik

Arkansas Children’s Research Institute

E

Ellen Van Der Plas

1University of Arkansas for Medical Sciences, Pediatric Hematology/Oncology, Little Rock, United States